Please ensure Javascript is enabled for purposes of website accessibility

US Consumer Spending Falls as Trump Tariff’s Muddle Economy

1 day ago

US Supreme Court Lets Parents Take Kids Out of Classes With LGBT Storybooks

1 day ago

In Win for Trump, US Supreme Court Limits Judges’ Power to Block Birthright Citizenship Order

2 days ago

California’s Newsom Sues Fox News for $787 Million for Defamation Over Trump Call

2 days ago

Motorcycle Collides With Tractor in Fatal Fresno County Collision

2 days ago

Fourth of July Celebrations Begin Saturday. Here’s Your Fresno Area Guide

2 days ago

Bill Moyers, Broadcaster and LBJ’s White House Press Secretary, Dies at 91

2 days ago

State Department Approves $30 Million for Gaza Humanitarian Foundation

2 days ago

Cargo Ship That Caught Fire Carrying Electric Vehicles Sinks in the Pacific

3 days ago

4 Million Acres of California Forests Could Lose Protection. What Trump’s ‘Roadless Rule’ Repeal Could Do

3 days ago
Alzheimer's Drug Shows Promise in Early Results of Study
gvw_ap_news
By Associated Press
Published 3 years ago on
September 28, 2022

Share

 

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.

The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.

Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s.

Patients were monitored using a scale that measures mental decline and their ability to do daily activities like getting dressed or feeding oneself.

Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish findings in a peer-reviewed medical journal.

The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug.

Researchers typically urge caution in evaluating a study until the full results are released. But the initial findings appear to be “quite robust” and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.

A statement from the Alzheimer’s Association called the findings the most encouraging to date for potential treatments of the underlying disease causes.

Some 6 million people in the U.S. and many more worldwide have Alzheimer’s, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks.

Alzheimer’s has no known cure. Long-standing treatments on the market just manage symptoms, and researchers don’t fully understand what causes the disease.

Last year, Biogen’s Aduhelm became the first new Alzheimer’s drug introduced in nearly two decades. But it has largely flopped after debuting with a price tag of $56,000 annually, which Biogen later slashed.

Doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage due to concerns over the drug’s high price tag and uncertain benefit.

Earlier this year, the federal Medicare program imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. Biogen announced afterward that it would stop most of its spending on the treatment.

Like Aduhelm, lecanemab, which Eisai developed, aims to clear a protein called beta-amyloid from the brain.

The protein forms a plaque that researchers believe is a contributor to Alzheimer’s. They also point to other potential factors like family history and chronic conditions such as diabetes.

Eisai executives say lecanemab focuses more on floating clumps of the protein before it forms the plaque, which is what Aduhelm targets.

Eli Lilly and Co. also is developing a potential treatment, donanemab, that targets the protein.

Shares of Cambridge, Massachusetts-based Biogen Inc. jumped 35% to $267.29 in Wednesday morning trading as the broader indexes edged higher. The stock had largely tumbled since Aduhelm’s debut last year.

Shares of Indianapolis-based Eli Lilly and Co. were up more than 8%.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

I Detest Netanyahu, but on Some Things He’s Actually Right

DON'T MISS

University of Virginia President Resigns Under Pressure From Trump Administration

DON'T MISS

How Did the Supreme Court Rule? Here’s a Look at the Big Cases

DON'T MISS

Mamdani’s NYC Primary Win Sparks Surge in Anti-Muslim Posts, Advocates Say

DON'T MISS

Trump Sends in DOGE to Slash Federal Gun Regulations by July 4

DON'T MISS

Tensions Flare at Announcement of Major Fresno County Gang Takedown

DON'T MISS

Measure C ‘Blackmailed’ As Fresno Enviro Coalition Gets Huge Say on Transportation Tax

DON'T MISS

Despite $49M Deficit, Fresno Unified Gives Top Brass 5% Raise, 3% One-Time Bonus

DON'T MISS

US Consumer Spending Falls as Trump Tariff’s Muddle Economy

DON'T MISS

US Supreme Court Preserves Key Element of Obamacare

UP NEXT

US Supreme Court Backs South Carolina Effort to Defund Planned Parenthood

UP NEXT

West Nile Virus Detected in Mosquitoes in Fresno County

UP NEXT

St. Agnes’ New Chief Medical Officer Is a Kidney Care Expert

UP NEXT

US Health Secretary Kennedy Says He Brought Back 722 CDC Employees, 220 at NIH

UP NEXT

Iran Says No Nuclear Talks Under Fire, UN Atomic Watchdog Urges Maximum Restraint

UP NEXT

Marijuana’s Links to Heart Attack and Stroke Are Becoming Clearer

UP NEXT

‘Little Lobbyists’ Urge Senators to Oppose Trump’s Bill Cutting Medicaid

UP NEXT

What Is Juneteenth and When Did It Become a US Federal Holiday?

UP NEXT

US B-2 Bombers, Bunker-Busters and Alternatives

UP NEXT

US Social Security, Medicare to Run Short of Funds in 2033, Trustees Say

Mamdani’s NYC Primary Win Sparks Surge in Anti-Muslim Posts, Advocates Say

16 hours ago

Trump Sends in DOGE to Slash Federal Gun Regulations by July 4

1 day ago

Tensions Flare at Announcement of Major Fresno County Gang Takedown

1 day ago

Measure C ‘Blackmailed’ As Fresno Enviro Coalition Gets Huge Say on Transportation Tax

1 day ago

Despite $49M Deficit, Fresno Unified Gives Top Brass 5% Raise, 3% One-Time Bonus

1 day ago

US Consumer Spending Falls as Trump Tariff’s Muddle Economy

1 day ago

US Supreme Court Preserves Key Element of Obamacare

1 day ago

US Supreme Court Lets Parents Take Kids Out of Classes With LGBT Storybooks

1 day ago

Fresno Unified Trustees Will Get Automatic Raises on Tuesday

2 days ago

Alleged ‘Fake’ ICE Agents Charged. Fresno Court Date Set

2 days ago

I Detest Netanyahu, but on Some Things He’s Actually Right

Like a lot of people of center-right/center-left political leanings, I’ve spent the past few decades detesting Prime Minister Benjamin Netan...

14 hours ago

2022 Election Rally for Netanyahu
14 hours ago

I Detest Netanyahu, but on Some Things He’s Actually Right

University of Virginia President James Ryan Resigns
14 hours ago

University of Virginia President Resigns Under Pressure From Trump Administration

15 hours ago

How Did the Supreme Court Rule? Here’s a Look at the Big Cases

Zohran Mamdani Speaks to Supporters
16 hours ago

Mamdani’s NYC Primary Win Sparks Surge in Anti-Muslim Posts, Advocates Say

American Flag Revolver
1 day ago

Trump Sends in DOGE to Slash Federal Gun Regulations by July 4

Rob_Bonta_Speaking_At_Press_Conference_1280x720
1 day ago

Tensions Flare at Announcement of Major Fresno County Gang Takedown

Garry_Bredefeld_Sandra_Celedon_Mesure_C_1280x720
1 day ago

Measure C ‘Blackmailed’ As Fresno Enviro Coalition Gets Huge Say on Transportation Tax

Fresno_Unified_Raises_1280x720
1 day ago

Despite $49M Deficit, Fresno Unified Gives Top Brass 5% Raise, 3% One-Time Bonus

Help continue the work that gets you the news that matters most.

Search

Send this to a friend